Forest candidate levomilnacipran fails to meet depression endpoint in Phase III trial
This article was originally published in Scrip
Executive Summary
Forest Laboratories said preliminary top-line results from a Phase III study of levomilnacipran to treat major depressive order failed to meet its goals. The compound is a single isomer of Savella (milnacipran HCl), Forest's approved SNRI for fibromyalgia, and two additional Phase III trials in depression are expected to report data in the second half of this year.